Phathom Pharmaceuticals (PHAT) Consolidated Net Income: 2022-2025
Historic Consolidated Net Income for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' Consolidated Net Income rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
- Latest data reveals that Phathom Pharmaceuticals reported Consolidated Net Income of -$30.0 million as of Q3 2025, which was up 60.39% from -$75.7 million recorded in Q2 2025.
- Phathom Pharmaceuticals' Consolidated Net Income's 5-year high stood at -$30.0 million during Q3 2025, with a 5-year trough of -$94.3 million in Q1 2025.
- For the 3-year period, Phathom Pharmaceuticals' Consolidated Net Income averaged around -$66.9 million, with its median value being -$75.7 million (2025).
- As far as peak fluctuations go, Phathom Pharmaceuticals' Consolidated Net Income slumped by 123.20% in 2024, and later spiked by 64.98% in 2025.
- Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Consolidated Net Income stood at -$55.0 million in 2022, then plummeted by 44.76% to -$79.6 million in 2023, then climbed by 6.36% to -$74.5 million in 2024, then skyrocketed by 64.98% to -$30.0 million in 2025.
- Its Consolidated Net Income was -$30.0 million in Q3 2025, compared to -$75.7 million in Q2 2025 and -$94.3 million in Q1 2025.